Company news

Dyadic International, Inc. news in 2026

Dyadic International, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Dyadic to Report Q3 2026 Financial Results and Host Conference Call on Thursday November 12, 2026

October 30, 2026

Dyadic International, Inc. Secures $2.9 Million Through Registered Direct Offering and Concurrent Private Placement

August 13, 2026

Dyadic Announces Second Quarter 2026 Financial Results Accelerating Commercialization Momentum Across Key Business Areas

August 12, 2026

Dyadic Expands Commercial Non-Animal Dairy Pipeline Through New Strategic Development Agreement

August 4, 2026

Dyadic to Report Q2 2026 Financial Results and Host Conference Call on Wednesday August 12, 2026

August 3, 2026

Dyadic Develops Stable C1 Cell Lines and Produces Purified Scripps-Designed Bundibugyo Ebola Antigens from Plasmids in Approximately 15 Days

July 28, 2026

Dyadic Announces Continued Listing on the Nasdaq Capital Market

July 24, 2026

Dyadic Expands Bio industrial Pipeline with New Proprietary Industrial Enzyme Program

July 16, 2026

Global Collaborations Continue to Validate Dyadic’s C1 Platform and Expands Commercial Potential

July 7, 2026

Dyadic Expands IP Protection and Business Development Activities in Japan

June 29, 2026

An Interview with the President & COO: How Dyadic is Commercializing Its Protein Platform Across Multi-Billion-Dollar Markets

June 21, 2026

Dyadic Highlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activities and Growing Commercial Adoption

June 15, 2026

Dyadic and Scripps Research Collaborate on Rapid-Response Hantavirus Antibody and Vaccine Development

May 28, 2026

Dyadic to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026

May 21, 2026

Dyadic Applied BioSolutions Announces Participation in Sidoti Virtual Investor Conference

May 19, 2026

Dyadic to Report Q1 2026 Financial Results and Host Conference Call on Wednesday May 13, 2026

April 29, 2026

Dyadic Announces 2025 Financial Results and Highlights Recent Company Progress

March 24, 2026

Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT Bioservices

March 15, 2026

Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing

March 13, 2026

Dyadic to Report 2025 Full Year Financial Results and Host Conference Call on Wednesday, March 25, 2026

March 11, 2026

Dyadic and Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free)

March 4, 2026

Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Milestone

March 1, 2026

Dyadic Applied BioSolutions and Proliant Health & Biologicals Announce Commercial Launch of Recombinant Human Albumin

February 17, 2026

Calls in 2026

Decks in 2026